FDA stamps OK on Uro­Gen's chemo gel — putting Liz Bar­rett and team's com­mer­cial chops to test amid pan­dem­ic

A year and three months af­ter Liz Bar­rett left No­var­tis’ on­col­o­gy group to helm one of Arie Bellde­grun’s less­er known biotech ven­tures, she is fi­nal­ly in a place to be­gin what she was brought in to do: steer its first drug in­to the mar­ket.

Uro­Gen Phar­ma has scored an OK for its hy­dro­gel for­mu­la­tion of the chemother­a­py mit­o­mycin, fol­low­ing the FDA’s pri­or­i­ty re­view for its use in low-grade up­per tract urothe­lial can­cer. Jelmy­to, as it will be known on the mar­ket, would be the first al­ter­na­tive to the in­va­sive sur­gi­cal pro­ce­dures that pa­tients are cur­rent­ly forced to en­dure.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER